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REVIEWS
Abstract: Chronic rhinosinusitis (CRS) is a chronic disease that affects 14.2% of the US
adult population. Despite being widespread, little is known about the etiology of CRS.
Treatment has been symptomatic and focused on relieving symptoms. Recent investigations
into causes of CRS have revealed that most CRS patients have an eosinophilic infiltration of
their nasal tissue (mucosa), regardless of atopy and elevated immunoglobulin E levels. Although
fungi are ubiquitous and in the nasal mucus of both healthy people and patients, it is only in
the patients that the eosinophils (part of the inflammatory response) are found. Fungi in the
nasal mucus are harmless, yet in CRS patients these same fungi stimulate an inflammatory
response, inducing the eosinophils to leave the blood vessels and enter the nasal and sinus
tissue and ultimately enter the nasal airway mucus. In the nasal mucus these eosinophils
attack the fungi and destroy the fungi by the release of a toxic substance called major basic
protein (MBP) from the granules in the eosinophils. This degranulation and release of the
toxic MBP not only destroys fungi, but also produces collateral damage injuring the nasal and
sinus mucosal lining tissue. The injury to the mucosal lining makes the nasal and sinus mucosa
susceptible to penetration and potential infection by bacteria. When this tissue inflammation
and damage is persistent and prolonged we call it CRS. The diagnosis of CRS is based largely
on symptomatic criteria, with anterior rhinoscopy or endoscopy, and, if there is any doubt
about the diagnosis, computed tomography imaging is employed to confirm the presence of
diseased sinus mucosa. Treatment of CRS, whether medical (intranasal corticosteroids, saline
irrigations) or surgical, is aimed at decreasing inflammation and obstruction in the sinonasal
passages. Antibiotics, although commonly used in CRS, should not be administered unless
there is suspicion of an acute bacterial infection. The theory behind the fungal and eosinophilic
etiology of CRS has led to use of an antifungal compound, intranasal Amphotericin B. In
clinical studies, topical irrigation with Amphotericin B has been shown to be both a safe and
effective treatment for CRS.
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Introduction
Chronic rhinosinusitis (CRS) is a chronic disease that involves long-term inflammation
of the nasal and paranasal sinus mucosa (Benninger et al 2003). It is an extremely
common condition, affecting 29.2 million (14.2%) US adults (Lethbridge-Çejku et
al 2004, 2006). Although commonly known as ‘chronic sinusitis’, the term ‘chronic
rhinosinusitis’ is now being used more frequently, due to the involvement of the
entire nasal and sinus passages seen with this condition (Benninger et al 2003). CRS
causes not only physical suffering, but also impacts psychological wellbeing and
daily functioning. CRS is estimated to result in an annual 18 to 22 million physician
office visits in the US (Benninger et al 2003).
Despite its widespread prevalence and substantial impact on the population, there
are no Food and Drug Administration-approved drugs for the management and
treatment of CRS. This is due largely to the lack of research into safe and effective
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treatments, which in turn is related to the lack of
understanding of the pathophysiology of the disease
(Meltzer et al 2004). This review will focus on current
thinking and evidence for the pathogenesis of CRS, as well
as current diagnostic methods and treatment options,
including the topical intranasal use of antifungal compounds.
Clinical definition
The term CRS encompasses all inflammatory disorders of
the nose and paranasal sinuses with a minimum duration of
12 weeks. This definition was put forth in 1996 by the
Rhinosinusitis Task Force (RSTF), which was established
by the American Academy of Otolaryngology—Head and
Neck Surgery (AAO-HNS) (Benninger et al 2003).
However, this definition does not include a specific etiology
for the eosinophilic inflammatory process.
Etiology and pathogenesis
CRS has a number of proposed causes. It is often attributed
to bacterial infection; a variety of aerobic (staphylococcus
spp., Gram-negative rods) and anaerobic (prevotella,
fusobacterium, peptostreptococcus) bacteria have been
cultured from patients with CRS (Meltzer et al 2004).
However, it is unclear if bacteria are causing infection, are
exposing the host to superantigens causing an inflammatory
response, or are able to colonize due to pre-existing
pathology of the sinus mucosa (Meltzer et al 2004).
A fairly recent concept in the pathogenesis of CRS is
colonization with fungi. Due to the presence of fungal spores
in the air, fungus is a common finding in the upper
respiratory tract even of healthy individuals. There are,
however, clinical subentities of CRS that have long been
attributed to fungal etiology. Allergic fungal rhinosinusitis
(AFRS) is a type of CRS in which patients have an allergic
response to the fungus colonizing the mucin in their
sinonasal cavities. In contrast, fungus balls are caused by
overgrowth of fungus in the nose and paranasal sinuses,
without an inflammatory reaction (Meltzer et al 2004). The
inflammatory reaction in response to a fungus ball is more
of an irritative inflammation, like a foreign body reaction,
ie, giant cells, and not an eosinophilic inflammation, which
is present in CRS.
Recent studies have attributed a much broader role to
fungi in CRS. It is postulated that in certain individuals,
colonizing fungi provoke a hypersensitivity response that
is non-immunoglobulin E (IgE)-mediated. Rather than an
allergic response, the fungi stimulate a local inflammatory
response with infiltration of eosinophils. This condition has
been termed eosinophilic fungal rhinosinusitis (EFRS), and
it has been implicated in the majority of cases of CRS
(Meltzer et al 2004).
The immune response in CRS patients is commonly a
partial Th2 lymphocyte response (production of interleukin
[IL]-5, IL-13, a small amount of IL-4); this is the immune
profile seen even among CRS patients who have a positive
skin response to fungal allergens, where one would expect
increased IL-4, as it is necessary for IgE synthesis (Hamilos
and Lund 2004) In fact, it seems that a universal immune
response in CRS is a T-cell response (a mix of Th1 and Th2
cells) with IL-5 as the most recognized mediator, IL-13,
and little IL-4 (Hamilos and Lund 2004). Although allergic
rhinitis can be present as a comorbid condition, the patient
with CRS alone exhibits eosinophilic mucin on histology,
without evidence for IgE-mediated allergy (Sasama et al
2005).
The mucin of CRS patients also contains fungal hyphae.
Ponikau and colleagues (1999) collected specimens from
210 patients with CRS (with or without polyposis) and found
that 96% were culture positive for multiple fungi, the most
common being Alternaria spp. (44.3%). Interestingly, 100%
of the 14 healthy controls also had positive fungal cultures,
with similar mycology. Other recent studies have found
similar results using fungal DNA detection with PCR
(Gosepath et al 2004). Therefore fungi are present in patients
with CRS and in healthy controls. The difference between
the CRS patients and the controls in this study was the
presence of eosinophils in tissue specimens (96% of 101
CRS surgical cases vs none of 4 controls). Fungi, only in
sensitized individuals, will initiate the eosinophilic reaction,
which targets the fungi in the mucous and allows the
degranulation of the eosinophils.
The authors hypothesized that the patients with CRS
were forming an eosinophilic reaction toward the fungal
hyphae in their sinonasal mucin; the eosinophils migrate
through the epithelium and degranulate in the mucin, causing
the inflammatory response (Ponikau et al 1999). It is likely
that it is the fungal antigen itself in patients with CRS, which
is able to induce migration and degranulation of the
eosinophils. This fungal antigen is derived from the
germinating fungal spores. Thus, it is the airborne fungal
spores, not a fungal colony itself which is required to induce
the immunologic cascade. Eosinophilic degranulation is
thought to cause the local tissue damage seen in CRS, mainly
through release of major basic protein (MBP). It appears
that MBP itself inflicts the epithelial damage directly because
of its toxicity (Frigas et al 1980; Harlin et al; Motojima et alTherapeutics and Clinical Risk Management 2007:3(2) 321
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1989). The airway remodeling, with basement membrane
thickening and epithelial damage, is similar to that seen from
the eosinophilic inflammatory process in asthma (Ponikau
et al 2003). In contrast to allergic rhinitis, in which the
eosinophils do not degranulate, they release only scant
amounts of MBP and they do not target fungi.
Meltzer and colleagues’ December 2004 definitions
subcategorized patients into those with and those without
polyps (Meltzer et al 2004). Meltzer and colleagues
suggested that patients without polyps may be a subcategory
of CRS in which the inflammatory cells in the mucin are
mostly neutrophils. Cases with polyps, however, were noted
to have eosinophilic inflammation. In contrast, Ponikau and
colleagues noted that, regardless of the presence or absence
of polyps, mucin from patients with CRS uniformly have
substantially elevated levels of MBP, a well-accepted
surrogate marker for eosinophilic migration and
degranulation (Ponikau, Sherris, Kephart, et al 2005). One
might postulate that, over time in CRS patients, this chronic
and debilitating disease with accumulation of mucosa may
result in polyps.
The common histopathologic denominator in CRS with,
and in some cases without, nasal polyposis, therefore, is
the eosinophilic infiltration into the nasal mucosa. This is
the histological hallmark of CRS in that the eosinophils are
present independently from atopy and are nearly absent in
healthy controls (Ponikau et al 1999). It is commonly
accepted that the role of eosinophils in the immune system
is the defense against large, nonphagocytosable pathogens
such as helminthic parasites (Gleich et al 1993).
Diagnosis
It is important to recognize the signs and symptoms
associated with the disease to be able to arrive at a diagnosis
of CRS. Through a careful patient history, the clinician
should be able to collect information on timing and severity
of symptoms associated with CRS (Meltzer et al 2004). The
RSTF developed a list of major and minor criteria (signs
and symptoms) to aid in diagnosis of rhinosinusitis (Table
1). CRS is probable if the patient has two or more major
factors or one major and two or more minor factors for more
than 12 weeks; CRS should be considered in the differential
diagnosis if the patient has one major factor or two or more
minor factors for more than 12 weeks (Benninger et al 2003).
It is also important to gauge the severity of the condition
in the patient as well as the impact on the patient’s quality
of life (QoL). A number of severity scoring systems and
QoL questionnaires have been developed for assessment of
CRS (Meltzer et al 2004). Quantifying the impact of CRS
on a patient’s daily functioning aids in determining future
patient outcomes with given treatments (Meltzer et al 2004).
In addition to history, physical signs are important
criteria in the diagnosis of CRS. Anterior rhinoscopy is a
noninvasive means of viewing the nasal mucosa (Meltzer
et al 2004). However, it is difficult to view beyond the
anterior portion of the nasal passages, even after
administration of topical decongestants. Nasal endoscopy,
although more invasive, is a preferable method for obtaining
a magnified view of the nasal mucosa, turbinates, and
interior of the nasal airway in the preoperative and post-
surgical patient. Endoscopy aids in assessing the integrity
of the mucosa, as well as directly seeing mucosal changes,
polyps, crusting, and/or discharge. Cultures can also be
obtained endoscopically (Meltzer et al 2004). Discolored
nasal discharge, polyps, or polypoid swelling seen with
anterior rhinoscopy or endoscopy, and edema or erythema
of the middle meatus or ethmoid bulla seen on endoscopy,
are consistent with CRS (Benninger et al 2003). If edema,
erythema, or granulation tissue do not extend to the middle
meatus or ethmoid bulla, radiologic imaging is necessary
to view the sinuses and to make or confirm the diagnosis of
CRS (Benninger et al 2003).
Imaging modalities are often necessary in CRS,
especially in patients with refractory or recurrent disease.
Plain film X-rays have not been proven to be useful in CRS.
Computed tomography (CT) scanning is the imaging method
of choice. Direct coronal CT affords an excellent view of
the bony structures and mucosal lining. These coronal CT
scans are indicated in patients with recurrent sinusitis or
CRS in order to properly consider treatment options and
sequence the steps in the evaluation. In surgical candidates,
Table 1 Factors associated with diagnosis of rhinosinusitis
(RSTF 1996) (Benninger et al 2003)
Major factors Minor factors
Facial pain/pressure* Headache
Nasal obstruction/ blockage Fever (all nonacute rhinosinusitis)
Nasal discharge/ purulence/ Halitosis
discolored postnasal drainage Fatigue
Hyposmia/ anosmia Dental pain
Purulence in nasal cavity on Cough
examination
Fever (acute rhinosinusitis only)
† Ear pain/ pressure/ fullness
Note: *Facial pain/pressure alone does not constitute a suggestive history for
rhinosinusitis in the absence of another major nasal symptom or sign; 
†Fever in
acute sinusitis alone does not constitute a strongly suggestive history for
rhinosinusitis in the absence of another major nasal symptom or sign.Therapeutics and Clinical Risk Management 2007:3(2) 322
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CT scanning clearly defines the surgical anatomy and the
extent of the disease process (Meltzer et al 2004) (Figures 1
and 2). Mucosal thickening, bony changes, or air-fluid levels
seen on CT are consistent with CRS (Benninger et al 2003).
There are instances when lateral or axial imaging is required
to determine the extent of the disease process. Magnetic
resonance imaging (MRI) is not recommended for diagnosis
of CRS due to its lack of specificity (Benninger et al 2003),
however, it is superior to CT for differentiation between
infectious (bacterial or viral) inflammation and fungal
concretions as well as in detecting malignancies (Meltzer
et al 2004). MRI can also detect extension of disease beyond
paranasal sinuses into the orbital region and intracranial
compartment (Benninger et al 2003).
Laboratory tests, such as nasal cytology, nasal biopsy,
and hematologic analyses are not necessary for the clinical
diagnosis of CRS. They can aid in determining whether other
conditions are present, such as acute bacterial infection or
allergy, or more serious conditions such as cystic fibrosis,
ciliary dysfunction, or various immunodeficiencies (Slavin
et al 2005).
Treatment
There are no definitive guidelines for the treatment of CRS
largely due to the lack of consensus on the etiology of the
disease (Benninger et al 2003). CRS has commonly been
treated with courses of oral antibiotics, but lack of clinical
evidence for their efficacy in CRS makes this therapy
controversial unless the patient is suffering from a
superimposed acute bacterial inflammation upon the
underlying chronic inflammatory condition (Slavin et al
2005). Unnecessary use of antibiotics in CRS may also
Figure 1 CT scan of normal sinuses (Tichenor 2006).
Note:         +, border of maxillary sinus; *, maxillary sinus ostium; C, concha bullosa; CT, computed tomography; E, ethmoid sinuses; IT, inferior turbinate; MT, middle
turbinate; S, septum; U, uncinate process.Therapeutics and Clinical Risk Management 2007:3(2) 323
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contribute to the problem of antibiotic-resistant bacteria.
There has been some use of inhaled topical antibiotics for
CRS; a few uncontrolled studies have reported efficacy with
these treatments, but controlled trials are needed to
demonstrate effectiveness of this therapy (Slavin et al 2005).
Antihistamines are not recommended for CRS, unless
the patient has an accompanying allergic rhinitis. Also,
although topical and oral decongestants are often used, side
effects such as rhinitis medicamentosa (with topical agents)
and hypertension (with oral agents) can occur (Slavin et al
2005). Intranasal corticosteroids have been shown to relieve
symptoms in CRS, but it is unclear if this is due to simply a
decrease in nasal congestion or to decreased inflammation
in the sinuses themselves. There is evidence that
corticosteroids (topical and oral) are effective against nasal
polyps (Slavin et al 2005). Studies have also shown that
irrigation with hypertonic saline alleviates symptoms in CRS
patients (Heatley et al 2001; Slavin et al 2005).
When there is documented underlying disease in CRS,
treatment of the underlying condition may help relieve CRS
symptoms as well. For example, intravenous
immunoglobulin (IVIG) therapy should be given to patients
with immunodeficiency, to prevent serious complications
due to CRS (subperiosteal and intracranial abscesses,
meningitis, sepsis, and death). Aspirin desensitization is
recommended in patients with aspirin-exacerbated airway
disease (Slavin et al 2005).
Surgery has long been a treatment of choice for persistent
CRS, and with the advent of endoscopy, most surgeries are
now minimally invasive. The main point of endoscopic sinus
surgery (ESS) is to clear blockage and ensure patency of
the osteomeatal complex (OMC) — the common drainage
Figure 2 CT scan of sinuses with sinusitis (Tichenor 2006).
Note:         +, thickening of the maxillary sinus; *, middle meatus; CT, computed tomography; E, ethmoid sinuses; M, maxillary sinus; O, maxillary sinus ostium; P, polyp.Therapeutics and Clinical Risk Management 2007:3(2) 324
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site of the frontal, maxillary, and anterior ethmoid sinuses
(Witterick and Kolenda 2004), which often plays a role in
perpetuation of the disease (Slavin et al 2005). Although
studies have shown positive outcomes from surgery, with
subjective improvement ranging from 70% to 98% of
patients, surgery does not necessarily cure the disease and
should be considered as an adjunct to medical therapy.
Medical treatment is often still required after surgery, but
possibly less frequently (Witterick and Kolenda 2004).
With current evidence pointing to the fungal etiology of
CRS, there has been a trend towards treatment of CRS with
topical antifungal medication, namely Amphotericin B
(AmB). AmB is a natural polyene antifungal that is not
absorbed through the gastrointestinal tract. AmB binds to
ergosterol, a component of cell walls of most fungi, leading
to formation of ion channels and cell death; AmB may also
act secondarily through oxidative damage to fungal cell
membranes through creation of free radicals from its own
oxidation (Groll et al 2003). It is hypothesized that topical
intranasal application of AmB can decrease the fungal load
in the sinonasal region, thereby decreasing the local
eosinophilic inflammatory reaction to fungal antigens seen
in many CRS patients (Ponikau, Sherris, Weaver, et al 2005).
The toxicity of intravenously administered AmB has been
well characterized at much higher concentrations than are
administered intranasally. There is clear evidence that AmB
is poorly absorbed through the gut when ingested orally,
therefore there is little or no potential for systemic exposure
to the drug when administered by the topical intranasal route
(Wise et al 1982; AmB PI 1996).
Although topical intranasal AmB has been considered
by some as a controversial therapy, there is increasing
evidence for the efficacy and safety of this antifungal drug
for CRS patients. In a 2002 pilot study, 75% of CRS patients
had improvement of symptoms, and 75% showed
improvement on endoscopic exam (Ponikau et al 2002). In
a study of 74 patients with persistent nasal polyposis despite
saline lavage and corticosteroid spray, addition of intranasal
AmB was associated with complete disappearance of polyps
in 39% of patients (Ricchetti et al 2002).
A randomized controlled study of CRS patients with
polyposis showed no improvement on CT and slightly worse
symptom scores for AmB patients (Weschta et al 2004).
However, this study excluded anyone with a clinical
suspicion of AFRS based on the Brent-Kuhn criteria
(Weschta et al 2004), the diagnostic criteria proposed for
AFRS. In the original Brunt-Kuhn criteria for allergic fungal
sinusitis (AFS), one needed positive allergy testing, the
presence of fungi on histology or culture, eosinophilic
“allergic mucin”, and the presence of positive evidence on
CT scan with nasal polyps. In the evidence based on our
studies, CRS does not require positive allergy testing (ie,
less than 50% of our patients had immunologic evidence of
allergy). These criteria have been demonstrated to be present
in the majority of CRS patients, placing the AFRS subentity
into question (Ponikau et al 1999).
More recently, a randomized controlled trial was
conducted with 30 CRS patients. This study demonstrated
improvement in CRS on CT scan in the AmB group at 6
months, with a mean decrease in mucosal thickening of 8.8%
compared with a mean increase of 2.3% for the placebo
group (p=0.03). In addition, 70% of the AmB patients had
improved endoscopy scores, and 9 out of 10 AmB patients
had improvement of symptoms as measured by SNOT-20
(compared with 6 of 14 placebo patients). The only adverse
event due to AmB was the feeling of burning at the time of
administration in 2 patients (Ponikau, Sherris, Weaver, et al
2005).
The majority of these studies suggest that AmB is an
effective means of decreasing mucosal inflammation and
improving symptoms in CRS patients. This positive effect
occurs, in all likelihood, by decreasing the fungal antigen
load, which in turn “shuts off” the eosinophilic response. It
appears that the initiation of the immunologic response is
the result of new hyphae, new spores, and this takes time
for the reaction to be modulated and reduced. If there are
antigenic portions of the fungi still present, it would initiate
the continuation of the immunologic response. Destroying
the fungi and reducing the amount of new hyphae and spores
in turn reduces the immunologic response of the body in
sensitized individuals. Therefore, this reduces the
degranulation of eosinophils and reduces the eosinophilic
population. Usually this reaction stops within a three month
period.
Conclusion
AmB is safe and generally well tolerated by patients because
is a topical therapy with minimal absorption. AmB should
therefore be considered as a first-line therapy in CRS prior
to considering surgical intervention. In patients with severe
and extensive nasal polyps, it is best to operate and surgically
remove the polyps and the mucus with its toxic MBP.
Surgical removal of obstructing polypoid disease allows
post-surgical access for the use of topical intranasal AmB
to prevent and minimize disease recurrence. The endoscopic
surgery to remove polyps with antrostomy allows AmB toTherapeutics and Clinical Risk Management 2007:3(2) 325
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gain access to the affected sinuses. Patients without prior
history of surgery or severe stage 4 polyposis might not
have as much benefit.
As the definitions and terms used to describe types of
CRS have changed, so have the theories behind the causes
of this common yet complex disease. With the currently
small amount of knowledge on the etiology and pathogenesis
of CRS, it remains a priority to treat the symptoms of CRS
by decreasing inflammation and obstruction, either
medically or surgically. However, as evidence emerges to
support the role of fungi in the pathogenesis of CRS,
intranasal topical antifungal treatment can be considered as
an early line of therapy to safely relieve the symptoms of
CRS and, in the post-surgical patient, to prevent or delay
recurrence.
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